- Home
- MRNS
as 12-18-2024 4:00pm EST
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 15.1M | IPO Year: | 2014 |
| Target Price: | $4.28 | AVG Volume (30 days): | 830.0K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.23 - $11.26 | Next Earning Date: | 11-12-2024 |
| Revenue: | $31,466,000 | Revenue Growth: | 1.63% |
| Revenue Growth (this year): | 15.71% | Revenue Growth (next year): | 40.57% |
Latest Marinus Pharmaceuticals Inc. News
MRNS Breaking Stock News: Dive into MRNS Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
Zacks
a month ago
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
a month ago
Marinus Pharmaceuticals: Q3 Earnings Snapshot
Business Wire
a month ago
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Clinical Trials Arena
2 months ago
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint
BioPharma Dive
2 months ago
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
MT Newswires
2 months ago
HC Wainwright Downgrades Marinus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $11
MT Newswires
2 months ago
TD Cowen Downgrades Marinus Pharmaceuticals to Hold From Buy
Compare MRNS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRNS Marinus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.